SOURCE: IO Circuit

August 09, 2007 06:30 ET

(OTC: VMCS) Segal Cancer Center Selects VisualMED

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit.

LAKE HARMONY, PA--(Marketwire - August 9, 2007) - VisualMED Clinical Solutions Corp. (the "Company") (OTCBB: VMCS) (FRANKFURT: VA6) announced the acquisition of VisualONCOLOGY, its state-of-the-art interactive, interdisciplinary electronic medical record by the Segal Cancer Center of the Mortimer B. Davis Jewish General Hospital of Montreal. The site, part of the McGill University teaching hospital system, will use VisualONCOLOGY for documentation of patient care, decision support and for the design and execution of protocol chemotherapy. Implementation is starting immediately with an anticipated go-live as early as Q4 of this year. The Cancer Center will take advantage of VisualONCOLOGY's fully electronic clinical documentation to free additional space for patient care, while VisualONCOLOGY's cohort-identification and protocol management capabilities will contribute directly to clinical research.

To read the complete release, go to http://biz.yahoo.com/iw/070808/0288130.html

Other active stocks are Flanders Corporation (NASDAQ: FLDR), Maxwell Technologies, Inc. (NASDAQ: MXWL) and Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send No Faxes or emails.

Contact Information